Literature DB >> 24345517

Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

Marta Di Forti1, Hannah Sallis2, Fabio Allegri3, Antonella Trotta4, Laura Ferraro5, Simona A Stilo6, Arianna Marconi4, Caterina La Cascia5, Tiago Reis Marques4, Carmine Pariante7, Paola Dazzan4, Valeria Mondelli7, Alessandra Paparelli4, Anna Kolliakou4, Diana Prata4, Fiona Gaughran4, Anthony S David4, Craig Morgan6, Daniel Stahl8, Mizanur Khondoker8, James H MacCabe4, Robin M Murray4.   

Abstract

UNLABELLED: Cannabis use is associated with an earlier age of onset of psychosis (AOP). However, the reasons for this remain debated.
METHODS: We applied a Cox proportional hazards model to 410 first-episode psychosis patients to investigate the association between gender, patterns of cannabis use, and AOP.
RESULTS: Patients with a history of cannabis use presented with their first episode of psychosis at a younger age (mean years = 28.2, SD = 8.0; median years = 27.1) than those who never used cannabis (mean years = 31.4, SD = 9.9; median years = 30.0; hazard ratio [HR] = 1.42; 95% CI: 1.16-1.74; P < .001). This association remained significant after controlling for gender (HR = 1.39; 95% CI: 1.11-1.68; P < .001). Those who had started cannabis at age 15 or younger had an earlier onset of psychosis (mean years = 27.0, SD = 6.2; median years = 26.9) than those who had started after 15 years (mean years = 29.1, SD = 8.5; median years = 27.8; HR = 1.40; 95% CI: 1.06-1.84; P = .050). Importantly, subjects who had been using high-potency cannabis (skunk-type) every day had the earliest onset (mean years = 25.2, SD = 6.3; median years = 24.6) compared to never users among all the groups tested (HR = 1.99; 95% CI: 1.50- 2.65; P < .0001); these daily users of high-potency cannabis had an onset an average of 6 years earlier than that of non-cannabis users.
CONCLUSIONS: Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.
© The Author 2013. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  age of onset; cannabis; drug use; gender; high-potency cannabis; psychotic disorders; survival plots

Mesh:

Year:  2013        PMID: 24345517      PMCID: PMC4193693          DOI: 10.1093/schbul/sbt181

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  35 in total

1.  Social environment, ethnicity and schizophrenia. A case-control study.

Authors:  Rosemarie Mallett; Julian Leff; Dinesh Bhugra; Dong Pang; Jing Hua Zhao
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2002-07       Impact factor: 4.328

Review 2.  Trajectories of brain development: point of vulnerability or window of opportunity?

Authors:  Susan L Andersen
Journal:  Neurosci Biobehav Rev       Date:  2003 Jan-Mar       Impact factor: 8.989

3.  The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors.

Authors:  Nicholas Myles; Hannah Newall; Olav Nielssen; Matthew Large
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults.

Authors:  John McGrath; Joy Welham; James Scott; Daniel Varghese; Louisa Degenhardt; Mohammad Reza Hayatbakhsh; Rosa Alati; Gail M Williams; William Bor; Jake M Najman
Journal:  Arch Gen Psychiatry       Date:  2010-03-01

5.  First cannabis use: does onset shift to younger ages? Findings from 1988 to 2003 from the Dutch National School Survey on Substance Use.

Authors:  Karin Monshouwer; Filip Smit; Ron de Graaf; Jim van Os; Wilma Vollebergh
Journal:  Addiction       Date:  2005-07       Impact factor: 6.526

6.  Determining the chronology and components of psychosis onset: The Nottingham Onset Schedule (NOS).

Authors:  Swaran P Singh; John E Cooper; Helen L Fisher; C Jane Tarrant; Tuhina Lloyd; Jumi Banjo; Sarah Corfe; Peter Jones
Journal:  Schizophr Res       Date:  2005-06-22       Impact factor: 4.939

7.  Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology.

Authors:  David J Potter; Peter Clark; Marc B Brown
Journal:  J Forensic Sci       Date:  2008-01       Impact factor: 1.832

8.  The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.

Authors:  Deepak Cyril D'Souza; Edward Perry; Lisa MacDougall; Yola Ammerman; Thomas Cooper; Yu-Te Wu; Gabriel Braley; Ralitza Gueorguieva; John Harrison Krystal
Journal:  Neuropsychopharmacology       Date:  2004-08       Impact factor: 7.853

9.  Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients.

Authors:  Michael T Compton; Mary E Kelley; Claire E Ramsay; Makenya Pringle; Sandra M Goulding; Michelle L Esterberg; Tarianna Stewart; Elaine F Walker
Journal:  Am J Psychiatry       Date:  2009-10-01       Impact factor: 18.112

10.  Substance use in a population-based clinic sample of people with first-episode psychosis.

Authors:  Jennifer H Barnett; Ursula Werners; Sandra M Secher; Katherine E Hill; Rossa Brazil; Kim Masson; David E Pernet; James B Kirkbride; Graham K Murray; Ed T Bullmore; Peter B Jones
Journal:  Br J Psychiatry       Date:  2007-06       Impact factor: 9.319

View more
  114 in total

1.  Genetic and Environmental Contributions to the Association Between Cannabis Use and Psychotic-Like Experiences in Young Adult Twins.

Authors:  Ragnar Nesvåg; Ted Reichborn-Kjennerud; Nathan A Gillespie; Gun Peggy Knudsen; Jørgen G Bramness; Kenneth S Kendler; Eivind Ystrom
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

2.  Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006-2015.

Authors:  Bridget Maloney-Hall; Sarah C Wallingford; Sarah Konefal; Matthew M Young
Journal:  Health Promot Chronic Dis Prev Can       Date:  2020-06       Impact factor: 3.240

Review 3.  Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Authors:  Marc W Manseau; Donald C Goff
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

4.  Persistent cannabis use among young adults with early psychosis receiving coordinated specialty care in the United States.

Authors:  Leslie Marino; Jennifer Scodes; Talia Richkin; Jean-Marie Alves-Bradford; Ilana Nossel; Melanie Wall; Lisa Dixon
Journal:  Schizophr Res       Date:  2020-05-28       Impact factor: 4.939

5.  Higher average potency across the United States is associated with progression to first cannabis use disorder symptom.

Authors:  Brooke J Arterberry; Hayley Treloar Padovano; Katherine T Foster; Robert A Zucker; Brian M Hicks
Journal:  Drug Alcohol Depend       Date:  2018-12-17       Impact factor: 4.492

Review 6.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

7.  State medical marijuana laws, cannabis use and cannabis use disorder among adults with elevated psychological distress.

Authors:  Ryan K McBain; Eunice C Wong; Joshua Breslau; Amy L Shearer; Matthew S Cefalu; Elizabeth Roth; M Audrey Burnam; Rebecca L Collins
Journal:  Drug Alcohol Depend       Date:  2020-07-24       Impact factor: 4.492

8.  Associations between Psychiatric Disorders and Cannabis-Related Disorders Documented in Electronic Health Records.

Authors:  Anne Campbell; Steffani R Bailey; Kim A Hoffman; Javier Ponce-Terashima; Katie Fankhauser; Miguel Marino; Dennis McCarty
Journal:  J Psychoactive Drugs       Date:  2020-04-15

Review 9.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

10.  Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed.

Authors:  Margaret Haney; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2015-08-19       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.